PQDx 0033-013-00 WHO
PQ Public Report
July/2016, version 5.0
PQDx 0183‐060‐00 WHO
PQ Public Report
October/2016, version 5.0
PQDx 0006-005-00 WHO
PQDx PR
February/2016, version 2.0
PQDx 0053-006-00 WHO
PQ Public Report
June/2016, version 2.0
PQDx 0018-010-00 WHO
PQDx PR
July/2016, version 3.0
PQDx 0214-064-00
WHO PQDx PR
April/2016, version 3.0
PQDx 0198-071-00
WHO PQDx PR
April/2016, version 2.0
PQDx 0005-005-00
WHO PQDx PR
May/2016, version 3.0
PQDx 0181-031-00
WHO PQ Public Report
March/2017, version 3.0
PLOS ONE | https://doi.org/10.1371/journal.pone.0192765 February 23, 2018
AIDSFree Case study series
This publication is made possible by the generous support of the American people through the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) and the U.S. Agency for International Development (USAID) under the terms of Cooperative Agreement AID-OAA-A-14-00046....
The contents are the responsibility of AIDSFree and do not necessarily reflect the views of PEPFAR, USAID, or the U.S. Government.
more
Strengthening Community responses to HIv Treatment and Prevention
Unite for Children
First Edition
Translating Community Research Into Global Policy Reform For National Action: A Checklist For Community Engagement To Implement The WHO Consolidated Guideline On The Sexual And Reproductive Health And Rights Of Women Living With HIV
3rd edition | December 2018
Policy
July 2012
Working Paper No. 3
Policy Brief
HIV testing services
December 2016
WHO/HIV/2016.21
The primary role of Benin’s Department of Pharmacy and Medicines (DPMED) is to develop and apply the national pharmaceutical policy. The main objective of this policy is to ensure the availability and accessibility of quality medicines for the population. To fulfill its mandate, DPMED aims to stre...ngthen its regulatory capacity, including the issuance of licenses to pharmaceutical establishments and the registration of pharmaceutical products. Benin’s current registration system shares core concerns that are common to most developing countries, notably the capacity to evaluate and monitor the security, efficacy, and quality of medicines and other health products. It is currently characterized by 1) poor or inadequate traceability of records or regulations (example: a product’s marketing authorization [MA] is often hard to find); 2) lack of evidence used in the regulatory decision-making process (reasons behind special import authorization, i.e., products without valid MAs); 3) inconsistent and unsecured archiving system; 4) limited human resources; and 5) an inefficient information management system
more